MSM
Patent #
5,569,679
| United States Patent |
5,569,679 |
| Jacob |
Oct. 29, 1996 |
Pharmacologic management of snoring
Abstract
A method of pharmaceutically managing snoring is provided by the instillation
intranasally of a solution containing 1-20% methylsulfonylmethane by weight
dissolved in water so as to saturate the nasal mucous membranes. Preferably, the
solution has between 10%-16% by weight methysulfonylmethane. The solution may be
buffered, and/or a mild analgesic may be included. The method prefers that
instillation occur as close to the sleep event as possible, and it should be at
least within one hour before a person retires for sleep. The solution may be
introduced by spray or drop-wise, and a product packaging the solution in a
suitable container is described.
| Inventors: |
Jacob; Stanley W. (Portland, OR). |
| Assignee: |
Russell A. Krueger Pharmaceuticals, Inc.
(Portland, OR). |
| Appl. No.: |
366,666 |
| Filed: |
Dec. 30, 1994 |
| Intl. Cl. : |
A61K 31/10, A61K 31/045 |
| Current U.S. Cl.:
|
514/711;
514/724;
514/923 |
| Field of Search: |
514/711, 923 |
References Cited | [Referenced
By]
U.S. Patent Documents
-
Other References
- "Y Snore Anti-Snoring Nose Drops" Product, Manufactured By
Datong Health Care, China.
Primary Examiner: Rollins; John W.
Attorney, Agent or Firm: Martin; Timothy J.
18 Claims, 3 Drawing Figures
| United States Patent |
5,569,679 |
| Jacob |
October 29, 1996 |
Pharmacologic management of snoring
Abstract
A method of pharmaceutically managing snoring is provided by the instillation
intranasally of a solution containing 1-20% methylsulfonylmethane by weight
dissolved in water so as to saturate the nasal mucous membranes. Preferably, the
solution has between 10%-16% by weight methysulfonylmethane. The solution may be
buffered, and/or a mild analgesic may be included. The method prefers that
instillation occur as close to the sleep event as possible, and it should be at
least within one hour before a person retires for sleep. The solution may be
introduced by spray or drop-wise, and a product packaging the solution in a
suitable container is described.
| Inventors: |
Jacob; Stanley W. (Portland, OR) |
| Assignee: |
Russell A. Krueger Pharmaceuticals, Inc.
(Portland, OR) |
| Appl. No.: |
366666 |
| Filed: |
December 30, 1994 |
| U.S. Class: |
514/711; 514/724;
514/923 |
| Intern'l Class: |
A61K 031/10; A61K 031/045 |
| Field of Search: |
514/711,923 |
References Cited [Referenced
By]
U.S. Patent Documents
| 4477469 |
Oct., 1984 |
Herschler |
514/588. |
| 4863748 |
Sep., 1989 |
Herschler |
426/72. |
Other References
|
"Y Snore Anti-Snoring Nose Drops" Product, Manufactured By
Datong Health Care, China. |
Primary Examiner: Rollins; John W.
Attorney, Agent or Firm: Martin; Timothy J.
Claims
1. A method of managing snoring comprising the step of instilling a solution
intranasally within a subject's nasal cavity wherein said solution includes
a carrier solvent containing an effective amount of methylsulfonylmethane as
a solute therein.
2. The method according to claim 1 wherein said solution also includes an
analgesic compound dissolved therein.
3. The method according to claim 2 wherein said analgesic compound is
menthol.
4. The method according to claim 1 wherein said solvent is water.
5. The method of claim 1 wherein said solvent is water and phosphate
buffered saline mixed in a ratio of 1:1 by volume.
6. The method according to claim 4 wherein the amount of
methylsulfonylmethane is between one percent (1%) and twenty percent (20%)
by weight, inclusively.
7. The method according to claim 4 wherein the amount of
methysulfonylmethane is between ten percent (10%) and sixteen percent (16%)
by weight, inclusively.
8. The method according to claim 1 wherein the solution is instilled as
spray.
9. The method according to claim 1 wherein the solution is instilled
drop-wise.
10. The method according to claim 1 wherein the solution is instilled within
one hour before the subject retires for sleep.
11. The method according to claim 10 wherein the solution is instilled one
half hour or less before the subject retires for sleep.
12. The method according to claim 1 wherein said solution is instilled in a
sufficient quantity to saturate the patient's nasal mucous membrane.
13. A product adapted for use in treating snoring, comprising:
(a) a solution including a solvent for methylsulfonylmethane, an analgesic
compound dissolved therein and an amount of methylsulfonylmethane between
one percent (1%) and twenty percent (20%), inclusively, by weight dissolved
therein; and
(b) a container for said solution, said container including applicator means
associated therewith for instilling said solution intranasally within a
patient's nasal cavity.
14. A product according to claim 13 wherein said applicator means is a
dropper.
15. A product according to claim 13 wherein said applicator means is an
aerosol nozzle.
16. A product according to claim 13 wherein said solvent is water.
17. A product according to claim 13 wherein said analgesic compound is
menthol.
18. A product according to claim 13 wherein said solvent is water and
phosphate buffered saline mixed in a ratio of 1:1 by volume.
Description
FIELD OF THE INVENTION
The present invention broadly concerns the management of snoring by reducing
the incidence or magnitude thereof. More particularly, however, the present
invention is directed to reducing or eliminating snoring by pharmacologic
means. This invention directly concerns the method of managing snoring by
the instillation of pharmacologic solutions into the nasal passageway.
BACKGROUND OF THE INVENTION
Snoring is an inspiratory sound which arises during a person's sleep.
Snoring is believed to be generally caused by the narrowing of the
nasopharyngeal airway such that turbulent airflow during relaxed breathing
vibrates the soft parts of the oropharyngeal passage, such as the soft
pallet, the posterior faucial pillars of the tonsils and the uvula. Many
causes for the narrowing of the nasal pharyngeal airway, especially during
sleep, exist, as noted below.
Snoring afflicts a large segment of the population, and is a condition
affecting both sexes of all ages. During wakefulness, a person is typically
able to consciously maintain the nasal pharyngeal passageway in an open
condition; however, with the onset of sleep, relaxation allows the
nasopharyngeal passageway to restrict, and snoring results. It has been
estimated that up to 45% of all adults snore occasionally with about 25%
being habitual snorers. Snoring increases with age, and it has been observed
that about 50% of men and 40% of women are habitual snorers by the age of
60. Lugaresi et al, "Snoring: Pathogenic, Clinical and Therapeutic
Aspects", Reported in Principles and Practice of Sleep Medicine (Kryger
et al, Editors 1989) at pp. 494-500.
A restricted nasopharyngeal passageway can occur anatomically. For example,
in children, this often is caused by obstruction due to enlarged tonsils or
adenoids. In adults, it is not unusual for the narrowing to be caused by
obesity. Further anatomical narrowing can be simple a matter of genetics
with some persons being predisposed towards a smaller nasopharyngeal
cross-section. A reduced nasopharyngeal passageway may also be caused by a
lack of muscle tone. Other anatomical conditions contributing to the
narrowing of the nasal pharyngeal passageway include choanal atresia, chrono
polyp, nasal septal deviation, nasal pharyngeal cyst, macroglossia,
retrognathia and micrognathia, but these less common. Leung et al, "The
ABZzzz's of Snoring", Post Graduate Medicine (Sep. 1, 1992).
Snoring may also be exacerbated by consuming either alcohol or drugs (such
as tranquilizers, sleeping pills and antihistamines) prior to bedtime.
Smoking can contribute to the incidence of snoring since cigarettes may
irritate the mucus membranes of the upper airway causing swelling and
increased mucus production.
Heretofore, it has been reported that there is no indication of
pharmacologic management of snoring. Douglas, "The Sleep Apnoea/Hypopnoea
Syndrome and Snoring", DMJ, Volume 306 (1993); Leung et al, "The
ABZzzz's of Snoring", Post Graduate Medicine (Sep. 1, 1992). However,
numerous management techniques have been described, depending upon the
perceived cause of snoring. None of these treatments have proved completely
adequate. Where snoring is caused or exacerbated by nasal allergy or an
upper respiratory track infection, these conditions may be treated
pharmacologically, but, as noted above, this is not deemed to be a
pharmacologic management of the overall snoring condition.
A basic treatment simply involves having the patient sleep in the prone
position or on his/her side. Sometimes this is stimulated by sewing a marble
or other object into the back of the snorer's clothes. Where the patient is
obese, treatment may be a program of weight loss. Along with these
treatments, of course, is the recommendation that the patient avoid use of
drugs, cigarettes or alcohol prior to bedtime so as to retard the loss of
oropharyngeal muscle tone.
Snoring can sometimes be managed by the use of an appliance. One example is
a custom-made mouth-piece constructed to move the snorer's lower jaw
forwardly, thus opening the airway. Another example is the use of a positive
pressure generator and face mask. These machines pump air through a hose and
nose/mouth face mask to keep air passages clear. Use of each of thee
devices, however, can cause the subject to have less restful sleep.
Another option for treating snoring is found with surgical techniques. In
children whose snoring is caused by an enlarge adenoids, and adenoidtotomy
is sometimes prescribed. Where tonsils are also enlarged, a tonsillectomy
often accompanies surgery to the adenoids. In adults,
uvulopalatopharyngoplasty may be recommended for habitual or heavy snorers.
Here, the surgeon resects the uvula, the distal portion of the soft pallet,
the anterior tonsillar pillars and the redundant lateral pharyngeal wall
mucosa. The purpose of such surgery, of course, is to increase the size of
the air passageway thereby allowing unobstructed movement of air through the
pharynx. Rates of success of the uvulopalatopharyngoplasty are uncertain,
with improvement reported to be in a range from 15% to 65%. Douglas,
"The Sleep Apnoea/Hypopnoea Syndrome And Snoring", British Medical
Journal, 1993, Vol. 306:1057-60. In some instances, surgical repair of a
deviated nasal septum has been shown to improve snoring.
Snoring, therefore, remains a serious problem for a large segment of the
population. Not only is it a nuisance, but can itself indicate a more
serious condition and, due to exhaustion resulting from lack of sleep, can
cause other problems. For example, an association between snoring and
hypertension has been found, and cardiac arrhythmia has been reported during
sleep apnea attacks. Snoring patients with decreased pulmonary function have
been shown to suffer from severe apnea. Not only is the risk of cessation of
breathing a danger for snoring, lack of oxygen due to an obstructed
nasopharyngeal passageway deprives the body of sufficient oxygen so that an
oxygen desaturation arises. Lack of oxygen may cause the brain to rouse the
sleeper just enough to take a breath without fully awaking. Since this may
happen hundreds of times a night, the snorer does not get sufficient sleep.
Moreover, being aroused from deep REM sleep on a repetitive basis may
increase heart rate and blood pressure. Thus, snoring may increase the risk
of heart attack and stroke, as noted above. Further, due to narcolepsy
resulting from exhaustion can cause a lack of attention for the snorer
during waking hours thus reducing productivity and even causing dangerous
situations should the exhausted snorer operate machinery or vehicles.
Accordingly, there has been a long felt need for improved management
techniques to reduce or eliminate snoring. Specifically, a long felt need
has existed for pharmacologic methodology in treating snoring which is
simple and safe to administer. The present invention is directed to such
pharmacological management technique.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a new and useful method
for the pharmacologic management of snoring.
Another object of the present invention is to provide a safe and relatively
effective pharmacologic treatment which can be self-administered by a snorer
prior to retiring for sleep.
Yet another object of the present invention is to provide an inexpensive
pharmacologic method to reduce the incidence and/or magnitude of snoring
that is safe and relatively effective for use.
Still a further object of the present invention is to provide a method
directed to the installation of methysulfonylmethane (MSM) into the nasal
passageway as a management technique for snoring.
Still another object of the present invention is to provide a product in the
form of a dispenser containing a methysulfonylmethane composition which may
be instilled by an applicator into the nasal passageway as a method of
reducing or eliminating the instance of snoring.
According to the present invention, then, a method for managing snoring is
provided by the step of instilling a solution intranasally within a
patient's nasal cavity wherein the solution includes a carrier solvent
containing an effective amount of methysulfonylmethane as a solute therein.
Preferably, the solvent is water, and the methysulfonylmethane is dissolved
therein within a range of 1% and 20% by weight, inclusively. The solvent may
also be water and phosphate buffered saline mixed in equal ratios.
Preferably, approximately 10% to 16% by weight of methysulfonylmethane is
used, and the solution is instilled into the nasal passageway as a spray or
drop-wise. The solution may contain a mild analgesic composition, if
desired. Examples of such analgesic compositions include: menthol, procaine,
xylocaine and the like. Regardless of the mechanism by which the solution is
instilled, it is preferred that the solution be instilled within one hour,
and preferably within an interval no more than ten minutes before the
patient retires for sleep. Moreover, an amount of solution should be
instilled of a sufficient quantity to saturate the patient's nasal mucus
membranes, typically on the order of 0.5 ml to 1.0 ml per nostril.
The present invention also includes a product which is adapted for use in
treating snoring. Here, the product is a solution containing a solvent for
methysulfonylmethane and an amount of methysulfonylmethane dissolved
therein. The solution is then packaged in a container. The container
includes an applicator associated therewith for instilling the solution
internasally within a patient's nasal cavity. In one embodiment, the
applicator is a dropper. In another embodiment, the applicator is an aerosol
nozzle, either providing a measured or unmeasured dosage of the solution
described above.
These and other objects of the present invention will become more readily
appreciated and understood from a consideration of the following detailed
description of the preferred embodiments when taken together with the
accompanying drawings, in which:
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a side view in elevation of a first exemplary embodiment of a
prior art container suitable for use with the present invention;
FIG. 2 is a side view in elevation of a second exemplary embodiment of a
prior art container suitable for use with the present invention; and
FIG. 3 is a side view in elevation of a third exemplary embodiment of a
prior art container and dropper suitable for use with the present invention;
DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS
The present invention concerns the pharmacologic management of snoring by
the instillation into the nasal passageway of a pharmacologic composition
containing an effective amount of dimethysulfone (DMSO.sub.2), also known as
methysulfonylmethane (MSM). Heretofore, relief of the snoring condition has
not readily responded to pharmacologic treatment. It has been surprisingly
found that methysulfonylmethane dissolved in a pharmaceutically acceptable
solvent when administered to saturate the mucous membranes of the nasal
passageways acts to reduce the instance of snoring for a time interval for
approximately 8-12 hours.
According to the present invention, then, a method of managing snoring has
been developed which comprises the step of instilling a solution
internasally within a patient's nasal cavity wherein the solution includes a
carrier solvent containing an effective amount of methylsulfonylmethane as a
solute therein. Preferably, the solvent is distilled water, although any
solvent which may dissolve the effective amount of methylsulfonylmethane
while at the same time being pharmaceutically acceptable for instillation
into the nasal cavity is suitable. Water and phosphate buffered saline,
mixed in a 1:1 ratio (equal proportions) by volume may serve as the solvent
as many patients prefer this mixture to plain distilled water. While any
suitable amount of methysulfonylmethane may be dissolved in the solvent up
to the saturation level, where the solvent is water, it is preferred that
the solution contain between 1% and 20%, by weight, inclusively, of
methylsulfonylmethane. An analgesic compound may be included within the
solution in order to minimize any unpleasant irritation. Such analgesic
compound may be menthol or any pharmaceutically acceptable local analgesic
composition such as procaine, xylocaine and the like, usually at dosages
less than 1/2% by weight. Where menthol is used, it is preferred that the
amount of menthol be 0.25% by weight.
The initial experiments to determine effectiveness of the instillation of
methylsulfonylmethane as a snoring reduction agent was carried out with an
initial sampling of 15 individuals. The empirical data collected for the
initial experiment is summarized in the following Table I.
TABLE I
______________________________________
% MSM
Subject Sex Age (by weight)
Results
______________________________________
AO M 56 16 R
US1 M 62 16 R
MD F 50 16 R
GC1 F 56 15 R
PH M 61 15 R
DM M 62 15 R
GC2 M 72 14 NR
EC M 76 14 R
DR M 83 14 R
RB M 56 13 R
MS F 69 13 R
AD M 50 13 NR
SJ M 70 12 R
US2 F 76 12 R
RP M 60 11 NR
______________________________________
R = Relief
NR = No Result
In each of the above cases, the subject was instructed to instill
approximately 0.5 to 1.0 milliliters (8-16 drops) of the solution containing
the methylsulfonylmethane approximately ten minutes to 1 hour prior to
retiring for sleep. The observation of the presence or absence of snoring
was made by the subject's mate. The observing party was not told that the
subject was employing internasal methylsulfonylmethane. As noted in Table I,
80% of the subject's mates reported the lessening or absence of snoring
while 20% reported no result from the internasal administration of the
methylsulfonylmethane.
A second sampling of subjects was undertaken wherein the weight percentage
of methylsulfonylmethane in water was varied at 10% and below. Results of
this study is summarized in the following Table II:
TABLE II
______________________________________
% MSM
Subject Sex Age (by weight)
Results
______________________________________
SC F 54 10% R
JB1 M 34 10% R
TC F 33 9% R
JP F 55 9% R
WW M 74 8% NR
CM F 54 7% R
RB2 M 62 6% R
HP M 42 6% R
WS M 65 6% R
JM F 49 5% R
KS M 40 4% R
JS M 60 3% R
SG M 52 2% R
RH M 59 1% R
JB2 M 60 1% NR
______________________________________
R = Relief
NR = No Result
While Table II demonstrates that relief of snoring occurred at
concentrations of as little as 1% methylsulfonylmethane by weight in water,
the relief was not reported to be as dramatic as at higher concentrations.
By warming the solution of water and methylsulfonylmethane to no more than
about 37.degree. C. (98.6.degree. F.), a greater concentration of
methylsulfonylmethane will go into solution. Accordingly, a third sampling
of four subjects employed such a warmed solution, and the results are
reported in Table III.
TABLE III
______________________________________
% MSM
Subject Sex Age (by weight)
Results
______________________________________
JB2 M 60 20% R
EL M 39 20% R
RF M 40 19% R
LW M 52 18% R
______________________________________
Here, it may be noted that subject JB2 responded positively to 20% by weight
methylsulfonylmethane whereas earlier the subject had shown no result to 1%
methylsulfonylmethane.
From the data derived from these experiments, as tabulated in Tables I-III,
it can be generally surmised that concentrations within a range of 1%-20%
methylsulfonylmethane by weight in water are effective. Observations
indicate that the higher concentrations within this range are the most
effective. However, due to the solubility of methylsulfonylmethane in water,
the best range for a useful method and product that avoids the need of
warming the solution is in the range of 10%-16% methylsulfonylmethane by
weight.
In order to determine whether the mere introduction of fluid against the
nasal membranes might have ameliorated the snoring of the subject, a saline
solution rather than the methylsulfonylmethane solution was substituted
after a period of time for the first five subjects listed in Table I.
Whereas relief had been present in all five subjects while receiving the
MSM/H.sub.2 O solution, when that solution was replaced with the saline
solution, snoring returned for all subjects on the initial night of the
substitution. This indicates that it is the saturation of the nasal membrane
with the MSM/H.sub.2 O solution that caused the desired effect. Moreover, it
was been observed that the positive effect of reduced snoring was achieved
the closer in time to retiring for sleep that instillation of the solution
occurs. Further, it has been observed that saturation of the nasal membranes
achieves the maximum effect. Several subjects reported that good results
occurred where the solution was re-instilled during the night were they
awakened from slumber.
In certain instances, some of the subjects in Table I observed minor
irritation upon introduction of the methylsulfonylmethane solution into the
nasal passageway. In order to minimize any irritation, a mild analgesic
compound was included in the solution. In one example, approximately 0.25%
by weight menthol was placed in solution. Of the patients who had
experienced irritation, about 1/3 indicated a preference for the menthol
solution while 2/3 preferred the solution without the menthol.
Alternatively, a majority of the subjects who received a solution made of
equal proportions of water and phosphate buffered saline indicated a
preference for the mixture over the simple water solution except for the
inconvenience of refrigeration needed to prevent deterioration of the
buffered phosphate. Refrigeration also reduces the amount of
methylsulfonylmethane which will remain in the solution.
With reference to FIGS. 1-3, it should be appreciated that the solution
according to the present invention may be administered through a variety of
known techniques, and the present invention is also directed to a product
that may be used in treating snoring. Here, the product may be in the form
of a solution including a solvent for methylsulfonylmethane and an amount of
methylsulfonylmethane dissolved therein. This solution is then packaged in a
container with the container included an applicator associated therewith for
instilling the solution internasally within a subject or patients nasal
cavity.
With reference to FIG. 1, a prior art container is shown which is of the
type used to instill a metered quantity of solution into the internasal
passageway. In FIG. 1, container 10 includes a bottle 12 for holding the
methylsulfonylmethane solution. Applicator 14 includes a metering pump 16
activated by a plunger 18. Upon depressing plunger 18 toward bottle 12, a
metered quantity of the solution in bottle 12 is ejected through nozzle 20
which is placed in the nostril. When not in use, container 10 is enclosed by
means cap 22 (shown in phantom). As noted, the container 10 is of a type
known in the prior art for administering a selected metered dosage.
A second prior art container is shown in FIG. 2. Here, container 40 includes
a plastic squeeze bottle 42 adapted to hold the fluid to be dispensed.
Plastic squeeze bottle 42 communicates with a nozzle 44 that is threaded at
46 to receive a cap 48 (shown in phantom). Here, bottle 42 may be held
upright with nozzle 44 positioned in the nostril. Upon squeezing, a mist of
solution from bottle 42 is ejected through nozzle 44. Alternatively, bottle
42 may be inverted with nozzle 44 in the nostril and the solution
administered drop-wise.
In FIG. 3, a standard eye dropper-type container 60 is shown which includes
a bottle 62 adapted to receive the fluid. Eye dropper 64 is received in
bottle 62 and is threadably mounted thereto by cap 66 mounted on threaded
neck 68. Eye dropper 64 includes a flexible bulb 70 which may be compressed
to remove air therefrom. By immersing tip 72 of pipette portion 74 in fluid,
the release of pressure on bulb 70 causes an amount of solution to be drawn
into pipette 74. Pipette 74 may then be placed into the nostril and the
solution administered in drop-wise manner.
Accordingly, the present invention has been described with some degree of
particularity directed to the exemplary embodiments of the present
invention. It should be appreciated, though, that the present invention is
defined by the following claims construed in light of the prior art so that
modifications or changes may be made to the exemplary embodiments of the
present invention without departing from the inventive concepts contained
herein.
* * * * *
SUBSCRIBE:
The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren.
You can view more than 50 back issues of this publication by clicking here.
The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter.
It is automatically published on the Tuesday night just before the first Wednesday of every month.
You can subscribe to this free monthly electronic letter by entering your eMail address and name below.
You will then automatically receive a request for confirmation, sent to whatever address you have entered.
If you do NOT receive this confirmation request, then you will not be subscribed.
There may have been an error with your address and you should resubmit.
The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription.
When you receive this confirmation request you must reply to it, or your subscription will not become active.
No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.
REMOVAL:
You can remove yourself from the subscription list in several different ways.
Click here to read about this entire newsletter system.
Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list.
If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed.
Thus, no one else can unsubscribe you, from some other computer, without your knowledge.
But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.
Personal Message:
When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions.
Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US.
You can select particular information you would like to receive, along with the free cassette tape and catalog.
You can reach Vibrant Life in many ways, including by mail to
Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504.
Within the US and Canada, use
the toll free number: (800) 523-4521,
the local number: (818) 558-1799,
the FAX: (818) 558-7299,
eMail to kimberly@oralchelation.com
or any one of the hundreds of message forms throughout the 50 web sites.
Vibrant Life normally ships the same day we get an order.
There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life.
Check out our companion site, at: http://www.oralchelation.net
where Karl's 2000 page book is published. Karl Loren is the author and
webmaster for this BOOK, as well as
for another web site about ORAL CHELATION.
His personal philosophical articles are at PHILOSOPHY.
Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED.
Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions:
One, that some form of copyright notice is included in every copy distributed or copied,
showing the copyright belonging to Vibrant Life, Burbank, CA, at
www.oralchelation.com .
The second condition is that the material is not to be used for any purpose contrary to
the purposes and objectives of this site.
This permission does not extend to materials on this site which are copyrighted by others.
